Study investigators evaluated patient and tumor characteristics to identify potential risk factors for first-year recurrence after cytoreductive nephrectomy for mRCC.

A majority of cancer drugs approved in the US during 2019-2022 had “clinical trial uncertainties,” research suggests.

55.8 percent of people with diabetes were diagnosed in 2023; 21.2 percent of those with diabetes had optimal glycemic concentrations.

NCD mortality declined in all high-income Western countries, with largest decline for both sexes in Denmark and smallest in U.S.

Anemia along with renal tubular damage (RTD) is associated with all-cause mortality in the general population, suggesting it’s a novel risk factor that could enhance prognostic ...

(HealthDay News) — Machine learning and deep learning models applied to integrated clinical and claims data can improve prediction of chronic kidney disease (CKD) progression to end-stage renal ...

(HealthDay News) — Consuming high levels of ultraprocessed foods is associated with increased levels of high-sensitivity C-reactive protein (hsCRP), according to a study published online Sept. 3 in ...

Adding TAR-200 to neoadjuvant cetrelimab improved the pCR rate in patients with muscle-invasive bladder cancer in a phase 2 trial.

Aldosterone increases blood pressure and contributes to chronic kidney disease (CKD) progression. Trial findings suggest baxdrostat may be an effective treatment.

Anrikefon is a kappa opioid receptor agonist with enhanced affinity for the receptor and minimal penetration of the blood-brain barrier.

Each additional Geriatric Oncology-PIM linked to 66 percent increase in odds of being mildly, moderate-to-severely frail at diagnosis.

Intervention resulted in a 17 percent absolute improvement in closing BP gaps, increased MA Star performance.